



(12) Translation of
European patent specification

(11) NO/EP 2925350 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 39/00 (2006.01)
A61P 35/00 (2006.01)
C07K 16/28 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.06.03
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.01.30
(86)	European Application Nr.	13811698.3
(86)	European Filing Date	2013.12.03
(87)	The European Application's Publication Date	2015.10.07
(30)	Priority	2012.12.03, US, 201261732760 P 2013.03.15, US, 201361801187 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, USA
(72)	Inventor	ENGELHARDT, John, J., c/o Bristol-Myers Squibb Company700 Bay Road, Redwood City, CA 94063, USA KORMAN, Alan, J., c/o Bristol-Myers Squibb Company700 Bay Road, Redwood City, CA 94063, USA QUIGLEY, Michael, c/o Bristol-Myers Squibb Company700 Bay Road, Redwood City, CA 94063, USA SELBY, Mark, J., c/o Bristol-Myers Squibb Company700 Bay Road, Redwood City, CA 94063, USA WANG, Changyu, 32264 Ashley Way, Union City, CA 94587, USA
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS
(56)	References Cited:	WO-A2-2007/048077 WO-A1-2007/133822 WO-A2-2008/137915 D. O'MAHONY ET AL: "A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy", CLINICAL CANCER RESEARCH, vol. 13, no. 3, 1 February 2007 (2007-02-01), pages 958-964, XP055100758, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-06-1974

C. USTUN ET AL: "Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?", BLOOD, vol. 118, no. 19, 10 November 2011 (2011-11-10), pages 5084-5095, XP055101216, ISSN: 0006-4971, DOI: 10.1182/blood-2011-07-365817

SIMPSON TYLER R ET AL: "Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 210, no. 9, 26 August 2013 (2013-08-26), pages 1695-1710, XP009176006, ISSN: 0022-1007 [retrieved on 2013-07-29]

BULLIARD YANNICK ET AL: "Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 210, no. 9, 26 August 2013 (2013-08-26), pages 1685-1693, XP009176020, ISSN: 0022-1007

M. J. SELBY ET AL: "Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells", CANCER IMMUNOLOGY RESEARCH, vol. 1, no. 1, 7 April 2013 (2013-04-07), pages 32-42, XP055100395, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-13-0013

W. LIN ET AL: "Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies", BLOOD, vol. 112, no. 3, 1 August 2008 (2008-08-01), pages 699-707, XP055037053, ISSN: 0006-4971, DOI: 10.1182/blood-2007-11-122465

STEFANIA LAURENT ET AL: "The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-[alpha] production", JOURNAL OF TRANSLATIONAL MEDICINE, vol. 11, no. 1, 1 January 2013 (2013-01-01), page 108, XP055100523, ISSN: 1479-5876, DOI: 10.1007/s00262-005-0668-3

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Claims

1. Et fucosylert ipilimumab for anvendelse i å behandle kreft.